PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

Published: July 2014
No. of Pages: 471

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.


Key Questions Answered

  • The current panel of standard ACS drugs are products of years or decades of research, development, and clinical research and are, in general, considered to be safe and effective in most cases. However, the rate of recurrent ACS events is unacceptably high. What are the major unmet clinical needs with regard to ACS event reduction and long term disease management?
  • Many of the ACS pipeline drugs will serve as add-on treatments to well-established standard-of-care therapies. How are drug companies exploiting novel therapies to drive market growth while simultaneously targeting niche patient populations? Which pipeline drugs will drive market growth?
  • The main-stream drugs in ACS have historically been predominantly small-molecule based. How will the entry of biologics into the ACS population at-large alter the dynamics of the market? Further, how will the clinic respond and adapt to biologic drug treatment strategies.
  • What unique drug-development strategies are companies using to shape the future and shift the trajectory of ACS treatment?

Key Findings

  • The highest-impact driver of the ACS market will be the launch of the PCSK9 inhibitors, human monoclonal antibody biologics that will be used to treat high LDL-C in addition to statins. Therapeutic novelty combined with biologic pricing will make the PCSK9s the largest contributors to ACS market growth, even if their use is reserved for niche or high-risk cases.
  • The entry of novel antithrombotic therapies, such as Xarelto, Zontivity, and cangrelor, into the ACS drug treatment space will also drive the expansion of the ACS market. These therapies will provide physicians with new treatment options that exploit unique targets. New therapies may be especially useful for patients at high risk or that have cardiovascular comorbidities that complicate the use of currently established SOC therapies.
  • Due to the maturity of the current ACS market, new therapies will exploit novel mechanisms of action and/or target orphan drug targets and are more likely to be utilized as add-on therapies to existing treatments. The pipeline predominantly treats established problems in new ways, leaving space for further innovation in the ACS space.


  • Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the ACS therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the gout therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ACS therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM ACS therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Published By: GlobalData
Product Code: GlobalData30953

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: